Clinical trial
A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in The MA.17 Study)
NCT00754845 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in The MA.17 Study)
- Lead sponsor
- Canadian Cancer Trials Group
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 23, 2004
- Completion date
- April 19, 2017
- Enrollment
- 1,918 (actual)
- Sites
- 43
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer